long intergenic non-protein coding RNA 1132Genealiases: []
Q-omics provides the consensus-scored LINC01132 profile across patient tissues and cancer cell-line models. LINC01132 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01132 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, LINC01132 RNA expression shows 16,556 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where LINC01132 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01132 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01132 survival associations across molecular data types. LINC01132 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01132 RNA expression–survival associations across cancer types. High LINC01132 expression shows unfavorable associations in LGG and KIRP, but favorable associations in KIRC, LUAD, HNSC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01132 RNA expression.
This table summarizes LINC01132 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01132. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01132 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, STAD, LIHC and BLCA. The COAD box plot shows higher LINC01132 RNA expression in tumor versus normal tissue (log2 FC = +0.576, t-test p < 0.001).
This table shows molecular features associated with LINC01132 in patient tissues and cancer cell lines. In patient samples, LINC01132 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
